Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Animalcare GroupLSE:ANCR 78 ROE % is 3.18% as of Dec. 2025, which is 58% above its 10-year median of 2.01. GuruFocus rates LSE:ANCR with a GF Score™ of 78/100 and a GF Value™ of £2.56 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 939 Drug Manufacturers companies, Animalcare Group ranks worse than 55.8% on this metric.
The historical rank and industry rank for Animalcare Group's ROE % or its related term are showing as below:
LSE:ANCR'
s ROE % Range Over the Past 10 Years
Min: -1.8 Med: 2.01 Max: 19.34
Current: 4.47
During the past 13 years, Animalcare Group's highest ROE % was 19.34%. The lowest was -1.80%. And the median was 2.01%.
LSE:ANCR's ROE % is ranked worse than 55.8% of 939
companies
in the Drug Manufacturers industry
Industry Median: 6.04
vs LSE:ANCR: 4.47
Animalcare Group (LSE:ANCR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Animalcare Group ROE % Related Terms
Animalcare Group ROE % Historical Data
* Premium members only.
The historical data trend for Animalcare Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Animalcare Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Animalcare Group ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Animalcare Group's ROE % distribution charts can be found below:
* The bar in red indicates where Animalcare Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Animalcare Group (LSE:ANCR) has a ROE % of 3.18% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Animalcare Group and its competitors. This is 58% above median its historical median of 2.01. According to the industry distribution chart, Animalcare Group ranks #524 out of 939 companies in the Drug Manufacturers industry, placing it in the top 55.8%.
Is Animalcare Group's ROE % too high?
Animalcare Group's current ROE % of 3.18% is 58% above median its 10-year median of 2.01. The Drug Manufacturers industry median ROE % is 6.04. Animalcare Group's value of 3.18% is 47.4% below this industry median. Based on the distribution chart, Animalcare Group ranks #524 out of 939 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Animalcare Group has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Animalcare Group's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Animalcare Group ranks #524 out of 939 companies for ROE %. This places Animalcare Group in the lower half of its industry. The industry median ROE % is 6.04. Animalcare Group's value of 3.18% is 47.4% below this benchmark. While the company's 10-year median is 2.01 vs. the industry median of 6.04, Animalcare Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.04, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Animalcare Group's current ROE % of 3.18% is 47.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Animalcare Group and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Animalcare Group's current ROE % is 3.18%, which is 58% above median its own 10-year median of 2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Animalcare Group stock overvalued right now?
Based on GuruFocus' analysis, Animalcare Group (LSE:ANCR) is currently considered Modestly Overvalued. The stock's GF Value™ is £2.56, compared to a current price of £3.34 — trading 30.3% above its estimated fair value. The current ROE % is 3.18%, which is 58% above median its 10-year median of 2.01 and 47.4% below the Drug Manufacturers industry median of 6.04. Animalcare Group's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Animalcare Group (LSE:ANCR), the current ROE % is 3.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Animalcare Group (LSE:ANCR) Overvalued in 2026?
Based on GuruFocus' analysis, Animalcare Group stock appears to be overvalued.
The current stock price of £3.34 is trading 30.3% above its estimated GF Value™ of £2.56.
GuruFocus considers Animalcare Group to be Modestly Overvalued.
Key valuation signals for LSE:ANCR:
ROE %: 3.18% (58% above median its 10-year median of 2.01)
GF Value™: £2.56 vs. price of £3.34 (30.3% above fair value)
Industry Position: 47.4% below the Drug Manufacturers median (#524 of 939)
No single metric tells the full story. See the LSE:ANCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Animalcare Group PLC is active in the healthcare division in the United Kingdom. It is a generic veterinary medicines company. The company mainly caters to veterinary professionals in the treatment of companion animals through a product line comprised of licensed veterinary medicines and companion animal identification products and services. The company operates in Animalcare Europe and Randlab segment. The company derives maximum revenue from the Animalcare Europe segment engaged in development and sale of veterinary pharmaceutical products in Europe and the European International Partners network. Geographically, the company derives maximum revenue from Europe region, followed by Asia-Pacific and other regions.
78GF Score
Get the complete analysis for LSE:ANCR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:ANCR has been successfully added to your 
